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Venturelli M, Layec G, Trinity J, Hart CR, Broxterman RM,
Richardson RS. Single passive leg movement-induced hyperemia: a
simple vascular function assessment without a chronotropic response. J
Appl Physiol 122: 28–37, 2017. First published November 10, 2016;
doi:10.1152/japplphysiol.00806.2016.—Passive leg movement (PLM)-
induced hyperemia is a novel approach to assess vascular function, with
a potential clinical role. However, in some instances, the varying
chronotropic response induced by PLM has been proposed to be a
potentially confounding factor. Therefore, we simplified and modified
the PLM model to require just a single PLM (sPLM), an approach that
may evoke a peripheral hemodynamic response, allowing a vascular
function assessment, but at the same time minimizing central re-
sponses. To both characterize and assess the utility of sPLM, in 12
healthy subjects, we measured heart rate (HR), stroke volume, cardiac
output (CO), mean arterial pressure (MAP), leg blood flow (LBF), and
calculated leg vascular conductance (LVC) during both standard
PLM, consisting of passive knee flexion and extension performed at 1
Hz for 60 s, and sPLM, consisting of only a single passive knee
flexion and extension over 1 s. During PLM, MAP transiently de-
creased (5! 1 mmHg), whereas both HR and CO increased from
baseline (6.0! 1.1 beats/min, and 0.8! 0.01 l/min, respectively).
Following sPLM, MAP fell similarly (5! 2 mmHg; P " 0.8), but
neither HR nor CO responses were identifiable. The peak LBF and
LVC response was similar for PLM (993! 189 ml/min; 11.9! 1.5
ml·min#1·mmHg#1, respectively) and sPLM (878! 119 ml/min;
10.9 ! 1.6 ml·min#1·mmHg#1, respectively). Thus sPLM represents
a variant of the PLM approach to assess vascular function that is more
easily performed and evokes a peripheral stimulus that induces a
significant hyperemia, but does not generate a potentially confound-
ing, chronotropic response, which may make sPLM more useful
clinically.
NEW & NOTEWORTHY Using the single passive leg movement
(PLM) technique, a variant of the vascular function assessment PLM,
we have identified a novel peripheral vascular assessment method that
is more easily performed than PLM, which, by not evoking potentially
confounding central hemodynamic responses, may be more useful
clinically.
flow-mediated dilation; endothelial function; cardiovascular disease
assessment
THE RECENT LITERATURE HAS underlined the clinical importance
of endothelial dysfunction in the pathophysiology of patients
with cardiovascular disease, Alzheimer’s disease, chronic ob-
structive pulmonary disease, type 2 diabetes, and even the
mortality of subjects in the intensive care unit (5, 9, 11, 12, 22,
23, 36). Therefore, vascular function testing should have a key
prognostic role in the clinical and preclinical phases of many
disease states; however, not a single assessment of vascular
function has been adopted as standard clinical care. Concern-
ing flow-mediated dilation (FMD) evoked by the hyperemic
response to ischemic cuff occlusion, first described by Cel-
ermajer and colleagues in 1992 (8), although not used clini-
cally, the results of research with this test have been both the
most long lived and accepted by the scientific and clinical
community. Much of the appeal of FMD can be linked to the
indication that this assessment represents nitric oxide (NO)-
mediated endothelial function and seems to be a surrogate for
coronary artery endothelial function (3). However, recent evi-
dence questioning the role of NO in FMD testing, but perhaps
more importantly concerns about the relatively complex meth-
odology and analyses (25, 28, 33, 39), has encouraged the
development of new approaches to assess vascular function
that can be more easily incorporated into standard clinical care.
Passive leg movement (PLM)-induced hyperemia is a novel,
noninvasive, and potentially clinically relevant assessment of
vascular function, championed by our group (14, 32) and
others (21). The PLM-induced vascular response also appears
to be predominantly NO mediated, but, by not relying on the
measurement of small changes in vessel diameter, has a meth-
odological advantage over FMD. However, some investiga-
tions have suggested that the hyperemic response to PLM is not
exclusively a consequence of the peripheral vasculature. In-
deed, several studies have underlined the potential role of
cardioacceleration (10, 24, 38) and, therefore, cardiac output
(CO) in this hyperemic response (18). Further supporting a
strong link to central hemodynamics, PLM, in the absence of
hyperemia, achieved by occluding the passively moved leg
with a cuff inflated to suprasystolic pressure, still induces
cardioacceleration and an increase in CO (18). This phenom-
enon can be explained by afferent feedback from skeletal
muscle (type III afferent fibers) that triggers the cardioaccel-
eration (10, 18, 24). Recently, to better understand the contri-
bution of these central hemodynamic responses to PLM, we
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studied young subjects with pharmacologically reduced neu-
rological feedback from mechanoreceptors in the moving limb
(31). This study revealed that the magnitude of peripheral
hemodynamic response to PLM does, in fact, appear to be
augmented by the central hemodynamic responses, with the
partial block of the afferents attenuating the hyperemic re-
sponse. The heart rate (HR)-driven increase in CO, which
likely helps to offset the fall in mean arterial pressure (MAP),
is probably the consequence of the PLM-induced vasodilation
in the leg and partially directly triggered by mechanoreceptor
feedback. Although not negating the use of PLM as a vascular
assessment, it would, perhaps, in certain scenarios, be useful to
minimize the impact of these potentially complicating central
hemodynamic responses. Indeed, in a recent study from our
group (37), the impact of quite different central hemodynamic
responses to limb movement in patients with heart failure and
healthy controls was parsed out by the use of both PLM and a
modified PLM approach, single PLM (sPLM). With just a
single movement, sPLM appears to generate a significant
peripheral hemodynamic response, but at the same time min-
imizes afferent feedback, eliminating changes in central hemo-
dynamics. However, although already demonstrating some
potential in the clinical arena, the sPLM response in young,
healthy subjects has yet to be thoroughly characterized.
Consequently, this study aimed to characterize the response
to sPLM by evaluating the central and peripheral hemodynam-
ics associated with both a standard continuous PLM and a
sPLM assessment in young, healthy subjects. With the expec-
tation of minimal afferent feedback, due the brevity of the
sPLM and the smaller peripheral vascular stimulus, we hypoth-
esized that 1) both HR and CO responses would be smaller
with sPLM than PLM, and 2) the peripheral vascular response
would be attenuated in sPLM compared with PLM, but the data
attained from both methods would be qualitatively similar.
METHODS
Subjects. Twelve young healthy men (28! 5 yr, 72 ! 8 kg,
178! 9 cm) participated in this study. None of the participants was
a smoker, and most were physically active. All procedures conformed
to the standards set forth by the Declaration of Helsinki and were
approved by the Institutional Review Boards of the University of
Utah, and the Salt Lake City VA Medical Center. Subjects gave
written, informed consent before their participation. Subjects reported
to the laboratory in the morning after an overnight fast and had not
exercised for the past 24 h.
PLM protocols. Subjects rested in the upright-seated position for 20
min before the start of data collection and remained in this position
throughout the study. The PLM protocol consisted of 60 s of resting
baseline central and peripheral hemodynamic data collection, fol-
lowed by 60 s of passive knee extension and flexion with the same
measures. PLM was performed by a member of the research team,
who moved the subject’s lower leg through a 90° range of motion
(180–90° knee joint angle) at 1 Hz. The sPLM protocol consisted of
60 s of resting baseline data collection followed by one passive knee
flexion and extension, which took 1 s, after which the leg was
maintained fully extended for the remaining 59 s of postmovement
data collection.
Knee angle. During each protocol, knee joint angle was continu-
ously recorded using a Vishay Spectrol 360-degree Smart Position
Sensor (Vashay Intertechnology, Malvern, PA) mounted on a BREG
X2K knee brace (BREG, Vista, CA) worn by each subject.
LBF and LVC. Measurements of arterial blood velocity and vessel
diameter were performed in the common femoral artery of the pas-
sively moved leg, distal to the inguinal ligament and proximal to the
deep and superficial femoral bifurcation with a Logiq-7 ultrasound
Doppler system (General Electric Medical Systems, Milwaukee, WI).
The ultrasound Doppler system was equipped with a 12- to 14-MHz
linear array transducer. Artery diameter was determined at a 90° angle
along the central axis of the scanned area. Blood velocity (Vmean) was
measured using the same probe utilizing a frequency of 5 MHz.
Measurements of Vmean were obtained with the probe positioned to
maintain an insonation angle of 60° or less, and the sample volume
was centered and maximized according to vessel size. Utilizing
arterial diameter and Vmean, leg blood flow (LBF) was calculated
second by second as:
LBF! Vmean · " · !vessel diameter ⁄ 2"2 · 60
where LBF is in milliliters per minute. Both anterograde and retro-
grade LBF were also calculated on a second-by-second basis. All
scanning and blinded analyses were performed by experienced and
skilled sonographers. Leg vascular conductance (LVC) was calculated
as LBF/MAP.
Central hemodynamics. HR, stroke volume (SV), CO, and MAP
were determined using a Finometer (Finapres Medical Systems, Am-
sterdam, The Netherlands). The photoplethysmographic cuff of the
finger pressure device was placed on the third finger of the left hand.
The subject’s arm was supported by an armrest to avoid arm and
finger movement. The Finometer signal was calibrated utilizing the
procedure indicated by the manufacturer. The height adjustment
sensor and reference were also positioned according to the manufac-
turer’s instructions. SV was estimated using the Modelflow algorithm
(Beatscope version 1.1a; Finapres Medical Systems) (6). CO was then
calculated as the product of HR and SV. The same method has been
documented to accurately track CO during exercise (4, 30).
Data collection and analysis. HR, SV, CO, MAP, ECG, and knee
joint angle underwent A/D conversion and were simultaneously ac-
quired (200 Hz) by commercially available data acquisition software
(AcqKnowledge, Biopac Systems, Goleta, CA). This software al-
lowed second-by-second analysis of HR, SV, CO, and MAP through-
out the PLM protocols. Vmean was analyzed with 1-Hz resolution on
the Doppler ultrasound system (GE Logiq-7) for 60 s at rest and the
first 60 s following the initiation of both PLM and sPLM. Maximal
absolute (peak), s ($peak), and the area under the curve (AUC) were
determined for each subject in all measured variables. In a subset of
these subjects (n " 4), the between-day (3 days) coefficient of
variation for LBF $peak for both sPLM and PLM was determined to
be 15%. The blood flow response to PLM and sPLM of a represen-
tative subject is illustrated in Fig. 1.
Statistical analysis. Two-way ANOVA was used to establish dif-
ferences between PLM and sPLM at rest as a result of the passive
movement. Following these analyses, where indicated, a Tukey post
hoc was used to define differences. Potential relationships between
variables were then analyzed using linear regression, and the corre-
sponding strength was assessed using Pearson correlation. The limits
of agreement between peak LBF, $peak LBF, and blood flow evoked
by PLM and sPLM were investigated by plotting the individual
differences against their respective means (Bland-Altman Plot). Sig-
nificance was set at an %-level of 0.05, and data are presented as
means! SE throughout the paper.
RESULTS
Central hemodynamics. The central responses to both PLM
and sPLM are summarized in Table 1. During PLM, all central
hemodynamic responses were transient (HR, SV, CO, and
MAP), changing shortly after the onset of PLM and returning
to baseline within 30 s. In contrast, the only central hemody-
namic response to sPLM was a transient fall in MAP (Fig. 2A).
Specifically, MAP was decreased from the 10th to 25th s
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($MAP: #5 ! 1 mmHg) and from the 9th to 22nd s ($MAP:
#5 ! 2 mmHg) for PLM and sPLM, respectively (Fig. 2A),
with no difference between either form of passive movement.
HR during PLM was significantly elevated, compared with
baseline, within 4 s, increased from 60 ! 3 beats/min to a
maximum of 67 ! 3 beats/min, and remained elevated for 22 s
(Fig. 2D). As sPLM did not stimulate any degree of cardioac-
celeration, peak, $peak, and AUC for HR were significantly
greater during PLM than as a result of sPLM. SV did not
change remarkably with either PLM or sPLM (Fig. 2C). CO
increased significantly above baseline after 4 s of PLM, reach-
ing a maximum of 7.0 ! 0.9 l/min ($CO: &0.77 ! 0.01
l/min), and then in 22 s decreased back to resting values. As
there was no distinguishable CO response to sPLM (Fig. 2B),
peak, $peak, and AUC for CO were all significantly greater
during PLM than as a result of sPLM.
LBF and LVC. The LBF response to PLM and sPLM is
summarized in Table 1 and illustrated in Fig. 3A. Baseline LBF
was similar before PLM (391 ! 68 ml/min) and sPLM
(376 ! 45 ml/min) and increased at the onset of both PLM and
sPLM. Specifically, during PLM, net LBF became significantly
elevated, compared with baseline, 5 s after the start of the
passive movement, reached a maximum value of 993 ! 189
ml/min ($LBF: 609 ! 115 ml/min), and within 35 s had
greatly decreased, yet remained elevated above baseline for the
duration of the passive movement (Fig. 3A). Similarly, in
response to sPLM net LBF became elevated at 3 s after the start
of the passive movement, reached a peak value of 878 ! 119
ml/min ($LBF: 522 ! 98 ml/min), but, in contrast to PLM,
returned to baseline levels within 19 s (Fig. 3A). Thus net LBF
was significantly elevated during the last 35 s of PLM com-
pared with sPLM. Furthermore, the AUC for the LBF response
was significantly greater for PLM (232 ! 82 ml) than as a
result of sPLM (116 ! 65 ml). However, the PLM and sPLM
LBF responses were reasonably well correlated, and a strong
agreement between the two protocols was apparent for peak
and $peak LBF (Fig. 4). Despite transient changes in MAP,
LVC essentially reflected the LBF responses, as illustrated in
Fig. 3B.
Anterograde and retrograde LBF. The anterograde and
retrograde LBF responses to PLM and sPLM are illustrated in
Fig. 5. Interestingly, the change in net LBF during PLM
comprised a significant increase in both anterograde and ret-
rograde LBF, whereas, in contrast, sPLM-induced hyperemia
was predominantly characterized by an increase in anterograde
LBF. Specifically, the blood velocity spectra during PLM
revealed a transient increase in the anterograde blood velocity,
the signal above the zero velocity line in Fig. 5A, and, with no
change in vessel diameter, this translated into an increase in
anterograde LBF (Fig. 5C). Additionally, after an initially
rapid, but transient, increase of ~5 s, retrograde blood velocity
progressively increased the signal below the zero velocity line
Day 1
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Fig. 1. Between-day (3 days) reproducibility of the blood flow response to continuous passive leg movement (PLM; A) and single PLM (sPLM; B) in a
representative subject. Horizontal dashed lines represent mean baseline values.
Table 1. Central and peripheral hemodynamics during continuous passive leg movement and single PLM
Peak $Peak AUC
PLM sPLM PLM sPLM PLM sPLM
Leg blood flow, ml/min 993 ! 189 878! 119 609 ! 115 522 ! 98 232 ! 82* 116 ! 65
Cardiac output, l/min 7.0! 0.9* 6.1! 0.7 0.77 ! 0.01* 0.01 ! 0.01 0.13 ! 0.03* 0.01 ! 0.01
Heart rate, beats/min 67! 3* 61 ! 3 6 ! 1* 1 ! 1 2 ! 0* 0 ! 0
Stroke volume, ml 109! 5 105 ! 4 5 ! 2 4 ! 2 1 ! 1 #1 ! 1
MAP, mmHg 81! 3 83 ! 2 #5 ! 1 #5 ! 2 #2 ! 0 #2 ! 1
Values are means! SE. PLM, passive leg movement; sPLM, single PLM; MAP, mean arterial pressure; AUC, area under the curve. *Significant difference
between methods.
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in Fig. 5A, and, with no change in vessel diameter, this
translated into an increase in retrograde LBF (Fig. 5D). Some-
what similarly to PLM, anterograde blood velocity and LBF
were significantly increased 2 s after the sPLM and remained
elevated for 25 s (Fig. 5, B and C). However, as noted, in
contrast to PLM, retrograde blood velocity and LBF increased
significantly during the sPLM, but, immediately after the
movement was completed, and for the subsequent 20-s retro-
grade, LBF was below prepassive movement baseline values
(Fig. 5, B and D).
DISCUSSION
With the ever-growing recognition that vascular dysfunction
is a precursor to the onset of many common pathologies, and
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Fig. 3. The leg blood flow (A) and leg vascular conductance (B) response to
continuous passive leg movement (PLM) and single PLM (sPLM). Values are
means ! SE. Horizontal dashed lines represent mean baseline values. *Sig-
nificantly different from PLM baseline. §Significantly different from sPLM
baseline. Shaded area indicates a significant difference between PLM and
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Fig. 2. Central hemodynamic responses to continuous passive leg movement
(PLM) and single PLM (sPLM) over time: mean arterial pressure (MAP; A),
cardiac output (CO; B), stroke volume (SV; C), and heart rate (HR; D). Values
are means! SE. Horizontal dashed lines represent mean baseline values.
*Significantly different from PLM baseline. §Significantly different from
sPLM baseline. Shaded area indicates a significant difference between PLM
and sPLM.
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Fig. 4. The correlations and agreement between peak leg blood flow (A and B), the change in peak leg blood flow ($peak; C and D), and blood flow (E and F)
evoked by continuous passive limb movement (PLM) and single PLM (sPLM). The relationships and agreement (Bland-Altman plots) between PLM and sPLM
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that not a single method to determine vascular function has
been adopted clinically, this study sought to thoroughly char-
acterize sPLM, a variant of PLM. It was anticipated that sPLM
would minimize central hemodynamic responses, but still fa-
cilitate the assessment of peripheral vascular function. Indeed,
and in line with our first hypothesis, sPLM, in comparison to
PLM, did not evoke a measurable increase in either HR or CO,
likely as a consequence of the minimal afferent feedback due
to the brevity of the sPLM. In our second hypothesis, we
predicted that, due to the reduced central hemodynamic re-
sponses and smaller peripheral stimulus, sPLM would yield
attenuated peripheral hemodynamic responses. Interestingly,
however, the variables that reflect the initial magnitude of the
peripheral hemodynamic response, such as peak LBF and
$peak LBF, were not statistically significantly different be-
tween PLM and sPLM, whereas the LBF AUC, which reflects
both the duration and magnitude of the response, was attenu-
ated. These data, in combination with the similar drop in MAP
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Fig. 5. Exemplar Doppler blood velocity spectra collected in the passively moved leg during continuous passive leg movement (PLM; A) and single PLM (sPLM;
B). Anterograde (C) and retrograde (D) blood flow in the passively moved leg during PLM and sPLM are shown. Values are means ! SE. Horizontal dashed
lines represent mean baseline values. *Significantly different from PLM baseline. §Significantly different from sPLM baseline. Shaded area indicates a significant
difference between PLM and sPLM.
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with both PLM and sPLM, suggest a somewhat minimal
impact of the central hemodynamic response on the initial
peripheral hemodynamic response. Furthermore, as antici-
pated, the PLM and sPLM LBF responses were reasonably
well correlated. These findings reveal that sPLM is a variant of
the PLM approach to assess vascular function that is more
easily performed and does not evoke potentially confounding
central hemodynamic responses, which may make sPLM more
useful clinically.
FMD, PLM, and sPLM. Vascular dysfunction is a key
prognostic factor in many clinical and preclinical pathophysi-
ological processes (5, 9, 11, 12, 22, 36). Therefore, the iden-
tification of progressive vascular dysfunction in the population
as a whole could have significant health care consequences by
alerting health care providers to the need to instigate interven-
tions and guide rehabilitation. However, there is currently not
a single vascular function assessment that has mustered wide-
spread clinical use. The method that has come the closest to
attaining this accolade is FMD, but the somewhat complex
nature of the data acquisition and, perhaps, recent reports
questioning the link between FMD and NO-related endothelial
function have kept this method on the fringe of clinical med-
icine (25, 28, 33, 39). Therefore, lately (7, 13, 20, 32), there has
been renewed interest in developing novel and potentially
clinically relevant approaches to assess vascular function.
PLM-induced hyperemia is a noninvasive approach to de-
termine NO-dependent vascular function with potential clinical
relevance that has been recognized by our group (14, 32) and
others (21). Compared with FMD, PLM is a significant meth-
odological improvement, requiring only the relatively easy
assessment of the passive movement-induced change in LBF
and not depending on small changes in conduit vessel diameter
as the major outcome variable. Therefore, PLM is a microvas-
cular assessment and not a measure of conduit function, which
may also be more clinically relevant. However, as with all
burgeoning techniques, PLM needs to be refined and questions
answered. Specifically, and from a practical standpoint, the
need to perform PLM for, originally, 3 min, although this study
has only focused on the first 60 s, which seems reasonable, and
concerns regarding the potential role of central hemodynamics
superimposed to differing degrees in various populations have
been aired (10, 24, 34, 35, 38). Indeed, the findings of this
investigation build on our laboratory’s previous work, in a
clinical population (37), now revealing that in young healthy
subjects sPLM, a variant of PLM, addresses both of these
methodological concerns by simplifying the peripheral vascu-
lar assessment, down to a single movement, and avoiding the
potentially confounding, or at least distracting, central hemo-
dynamic responses. However, the utility of this new method for
the vascular function assessment is not only based on the
simplicity of the protocol. Indeed, it is also important to note
that the lack of discomfort, associated with the 5-min cuff
occlusion employed during FMD testing, will also, likely,
facilitate the use of sPLM on a greater range of clinical and
preclinical populations. Furthermore, in the relatively common
case of a proximal split in the brachial artery, where FMD
cannot be validly performed, sPLM would be unaffected by
this issue. Therefore, sPLM may be a clinically useful ap-
proach with which to routinely assess vascular function in
health and disease.
The role of central hemodynamics in movement-induced
hyperemia. The comprehensive analysis of central and periph-
eral hemodynamics, during PLM and sPLM, afforded the
opportunity to evaluate which factors contribute to leg move-
ment-induced hyperemia. In addition to the robust increase in
both LBF and LVC (Fig. 3), PLM also evoked a rapid rise in
both HR and CO, likely a result of afferent feedback from joint
and muscle mechanoreceptors (Fig. 2) (1, 2, 15, 31). However,
concomitant with these responses to PLM, as is commonly
observed in young healthy subjects (18), despite the increase in
CO, there was a small, but significant, decrease in MAP of ~5
mmHg (Fig. 2). This fall in MAP was likely the consequence
of the acute vasodilation in the passively moved leg, but with
PLM it cannot be discerned if the baroreflex response to this
pressure change also contributed to the proposed afferent
driven increase in HR and CO (Fig. 2). Nevertheless, although
it is pressure and resistance across the leg that determine LBF
(Ohm’s law), this increase in CO could be an essential com-
ponent of the PLM response as CO is, systemically, linked to
MAP. Specifically, it appears that, at the onset of PLM, LVC
increases, driven by mechanically induced vasodilation (29)
and shear stress-induced FMD (16, 26), to such an extent that,
not only does MAP fall, but, in the face of this fall, the greatly
increased LVC facilitates an increase in LBF. The PLM-
induced increase in CO likely plays an important role in
limiting this fall in MAP, which could soon outstrip the rise in
LVC and not elicit an increase in LBF. However, by only
examining the PLM-induced responses, which include an in-
crease in HR and CO, this is difficult to discern.
By utilizing sPLM, employed to reduce the amount of
afferent feedback from joint and muscle mechanoreceptors
(1/60 compared with PLM), the central hemodynamic re-
sponses, HR and CO, were, as anticipated, ablated (Fig. 2).
Interestingly, however, despite the absence of cardioaccelera-
tion and therefore no increase in CO, peak hyperemia was
similar to the peak PLM LBF response. Additionally, it should
be noted that, although of undetermined origin, this increase in
LBF with PLM, without a central hemodynamic response,
suggests a simultaneous vasoconstriction somewhere in the
circulatory system.
Furthermore, the sPLM-induced fall in MAP (~5 mmHg)
was of a similar magnitude to the PLM response (Fig. 2). These
findings afford the unique opportunity to better understand the
role of central hemodynamics in movement-induced hyper-
emia. Specifically, the lack of a HR and CO response with
sPLM, but a similar fall in MAP compared with PLM, implies
that the main drive to increase central hemodynamic responses
is, indeed, afferent feedback from joint and muscle mechano-
receptors, and not the baroreflex, which, if a key player, would
have been evoked by the similar drop in MAP in both sPLM
and PLM. It is also clear from this comparison of the sPLM
and PLM responses that, with these passive movement inter-
ventions, there is likely a minimal role for CO in protecting
MAP and, therefore, facilitating the movement-induced in-
crease in LBF. This is based on the observation that, despite an
unchanged CO with sPLM, both the movement-induced in-
crease in LBF and the subsequent fall in MAP were not
different from PLM in which there was a significant central
hemodynamic response (Figs. 1 and 2). It is also important to
note that these impressively similar initial peak LBF and LVC
responses to sPLM and PLM, occurring in the first 10–15 s
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(Fig. 3), were the consequence of just one knee flexion and
extension in the case of sPLM, which occurred over just 1 s.
Indeed, the PLM and sPLM peripheral hemodynamic re-
sponses were reasonably well correlated, with the relationship
between the three indexes of LBF illustrated in Fig. 4. It is
important to note, as documented by the Bland-Altman plots,
that the congruence of peak LBF evoked during PLM and
sPLM was high (Fig. 4B), while the agreement between LBF
$peak and AUC was less strong (Fig. 4, D and F). Neverthe-
less, over time there were some clear differences between the
sPLM and PLM responses. For instance, the duration of the
sPLM-induced hyperemia was shorter, returning to baseline in
~20 s, whereas in PLM, LBF and LVC were still elevated at 60
s (Fig. 3). However, unfortunately, in this particular case, the
role of central hemodynamics and the sustained passive move-
ment cannot be parsed out so simply, although the timing of
responses and the information gleaned from the mechanical
influences of the passive movement (below) again support a
negligible role for both HR and CO.
Taken together, these findings suggest that the central he-
modynamic responses to PLM (HR and CO) are evoked by
afferent feedback and not the baroreflex. However, at least in
terms of the initial response to the passive movement, HR and
CO appear to play a minimal role in the passive movement-
induced hyperemia, as evidenced by a similar fall in MAP and
increase in LBF without these responses. Regardless, in addi-
tion to the relative simplicity of performance, sPLM minimizes
the potentially complicating, or at least distracting, central
hemodynamic responses, while still producing a related and
robust peripheral hemodynamic response that can be used to
assess vascular function.
Mechanical determinants of movement-induced hyperemia.
During PLM, net LBF was significantly elevated within 4 s of
the passive movement beginning and remained elevated for at
least 60 s. This net PLM LBF response comprised an increase
in both anterograde and retrograde blood flow, with the mag-
nitude of change in anterograde flow being greater than the
magnitude of change in retrograde flow (Fig. 5). Interestingly,
after the initial rapid peak response, the anterograde blood flow
fell, but remained elevated, while the retrograde blood flow
rose to become different from baseline and remained elevated.
These responses are likely attributable to the continuous re-
peated muscle length-dependent changes in vessel tortuosity
that produced intermittent periods of oscillating vascular resis-
tance. Indeed, in a previous investigation from our group (19),
it was revealed that femoral artery blood flow is clearly
influenced by knee joint angle. Specifically, femoral artery
blood flow was documented to increase as the knee was
extended from the lower (90°) to the middle and upper (180°)
range of knee joint angle. It was concluded that the factors
likely resulting in this response were muscle length-dependent
changes in capillary tortuosity and vessel diameter (17, 27).
Although in the present study both the central hemodynamic
responses (HR and CO) were evoked beyond the initial re-
sponse to PLM, the timing of the HR and CO responses (Fig.
2) and the information gleaned from the anterograde and
retrograde LBF responses over time (Fig. 5) suggest a negli-
gible role for both HR and CO and a more likely important
contribution from the repeated passive movements in terms of
the sustained PLM-induced blood flow. The effect of the
continued movement is likely both mechanical and physiolog-
ical in that the repetitive movements probably continue to
stimulate NO release, but perhaps in a more complex fashion
than with just a single movement. However, it should be
recognized that a limitation of this study was the lack of an
attempt to block NO synthase during sPLM, which warrants
further investigation to better elucidate the role of NO in these
two paradigms.
As a consequence of sPLM, net LBF was also significantly
elevated within 3 s of commencing the single and only passive
movement, but, in contrast to the PLM, LBF returned to
baseline levels in ~20 s. Interestingly, this increase in net LBF
was only composed of an increase in anterograde blood flow
(Fig. 5), with retrograde blood flow only being significantly
increased during the single knee flexion of the sPLM, follow-
ing which retrograde blood flow was clearly reduced for 20 s
(Fig. 5, B and D). These data are highly supportive of the
contention that LBF during passive movement is influenced by
knee joint angle subsequent to changes in muscle length-
dependent vessel tortuosity, vessel diameter, and, conse-
quently, resistance. Thus the rapid and very short-lived in-
crease in retrograde blood flow associated with the knee flexion
in sPLM (Fig. 5, B and D) was likely induced by an acute, joint
angle-related increase in vascular resistance. During the sub-
sequent knee extension, and then the maintenance of muscle
length for the following 59 s, vascular resistance was clearly
decreased, leading to a transient period of diminished retro-
grade blood flow.
Taken together, these findings suggest that there are, indeed,
significant mechanical determinants of passive movement-
induced hyperemia. Specifically, knee-joint angle indirectly
alters muscle and vessel geometry, both of which can facilitate
or impede LBF. However, whether the leg was exposed to
either PLM or sPLM, the initial peripheral hemodynamic
responses were very similar. In terms of the sustained increase
in LBF with PLM, although a role for the central hemodynamic
responses cannot be ruled out, there is likely an important
contribution from the repeated passive movements, both me-
chanically and physiologically, due to the continued vasodila-
tory stimulus.
In conclusion, this study sought to characterize sPLM, a
variant of the vascular function assessment PLM, which, due to
simplicity, may be more clinically useful than conventional
PLM. Somewhat unexpectedly, despite a lack of central hemo-
dynamic responses and a smaller peripheral stimulus, the initial
magnitude of the peripheral hemodynamic response, as as-
sessed by peak LBF and $peak LBF, was not significantly
different between sPLM and PLM. These data, in combination
with the similar drop in MAP with both PLM and sPLM, imply
a somewhat minimal impact of the central hemodynamic re-
sponse on the peripheral hemodynamic response to passive
movement. These findings document that the more easily
performed sPLM does not evoke a potentially confounding
central hemodynamic response, but does afford a similar as-
sessment of peripheral vascular function, potentially making
sPLM more useful clinically.
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